Advertisement

Topics

InflaRx gets European nod to begin phase II study with IFX─1 in patients with ANCA─associated vasculitis

15:49 EST 22 Dec 2018 | PharmaBiz

InflaRx N.V, a clinical─stage biopharmaceutical company, announced the approval of an Investigational Medicinal Product Dossier (IMPD) from the European regulatory authorities, allowing InflaRx to initiate a phase II

Original Article: InflaRx gets European nod to begin phase II study with IFX─1 in patients with ANCA─associated vasculitis

NEXT ARTICLE

More From BioPortfolio on "InflaRx gets European nod to begin phase II study with IFX─1 in patients with ANCA─associated vasculitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...